tradingkey.logo
tradingkey.logo
Search

BioMarin Presents Five-Year Phase 3 Results Reinforcing Long-Term Efficacy and Safety of ROCTAVIAN®

ReutersJun 24, 2025 1:04 PM
facebooktwitterlinkedin

- Biomarin Pharmaceutical Inc BMRN.O:

  • BIOMARIN PRESENTS FIVE-YEAR PHASE 3 RESULTS REINFORCING LONG-TERM EFFICACY AND SAFETY OF ROCTAVIAN® (VALOCTOCOGENE ROXAPARVOVEC-RVOX) AT INTERNATIONAL SOCIETY ON THROMBOSIS AND HAEMOSTASIS 2025 CONGRESS

  • BIOMARIN PHARMACEUTICAL INC - NO NEW SAFETY SIGNALS OBSERVED IN 5-YEAR ROCTAVIAN STUDY

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Recommended Articles

Tradingkey
KeyAI